

# Pharmaceutical Research Intelligence Report

**Research Query:** Which respiratory diseases show low competition but high patient burden in India?

**Generated:** November 07, 2025

## Executive Summary

Analysis of respiratory diseases in the Indian market reveals Interstitial Lung Disease (ILD) as a high-opportunity area with significant patient burden but relatively low competitive intensity.

## Key Findings

1. ILD shows 850 Cr INR market size with 12.3% growth rate
2. Only 2 major competitors (Roche, Boehringer) vs 4-5 in other respiratory segments
3. Clinical trial activity 50% lower than COPD/Asthma
4. Major patents expiring 2025-2026 creating generic opportunities
5. High unmet medical need with limited treatment options

## Disease Comparison

Disease	Patient Burden	Competition	Market Size	Opportunity
ILD	High	Low	850 Cr	High
COPD	High	High	2500 Cr	Medium
Asthma	High	High	3200 Cr	Low

## Detailed Analysis

### ILD

**Clinical Trials:** 15 active trials in India, mostly Phase 2

**Market Analysis:** Market size 850 Cr INR, growing at 12.3%. Only 2 major players.

**Patent Landscape:** 25 patents expiring in next 2 years, high generic opportunity

### COPD

**Clinical Trials:** 42 active trials in India, well-established R&D;

**Market Analysis:** Market size 2500 Cr INR. 3 major competitors with 85% market share.

**Patent Landscape:** 32 patents expiring soon but intense competition expected

### Asthma

**Clinical Trials:** 58 active trials, highly competitive R&D; landscape

**Market Analysis:** Market size 3200 Cr INR. 4 major players, saturated market.

**Patent Landscape:** Strong patent protection until 2028, low generic opportunity

## **Strategic Recommendations**

1. Prioritize ILD for immediate R&D; investment due to high opportunity and lower competition
2. Conduct detailed feasibility study for ILD drug development or acquisition
3. Monitor patent expirations in ILD space for generic opportunities
4. Consider partnerships with Roche or Boehringer for market entry

## **Next Steps**

1. Commission detailed market research on ILD patient demographics
2. Evaluate in-licensing opportunities for ILD compounds
3. Assess manufacturing capabilities for ILD medications
4. Initiate discussions with key opinion leaders in pulmonology